# Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies

Source: https://onco.cc/trials/nct07472933/  
OnCo record `nct07472933` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by West China Hospital, not yet recruiting.

## Summary

Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies is a phase 2 interventional study registered as NCT07472933 by West China Hospital, with a registry enrolment figure of 49 participants, started 2026-08-01 and due to reach its primary completion in 2028-02-29. Interventions recorded: Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors. Conditions listed: Cancer of Biliary Duct. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07472933
- Phase: 2
- Setting: An Exploratory Study of Vedotin-tislelizumab Combined With Toripalimab in EGFR-positive Refractory Advanced Biliary Tract Malignancies
- Sponsor: West China Hospital
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT07472933: https://clinicaltrials.gov/study/NCT07472933

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07472933.json